News

Civica Announces Leadership Transition

Civica Chief Operating Officer Ned McCoy to Serve as Civica’s Next President and Chief Executive Officer. Martin VanTrieste to Retire as CEO; Will Continue Serving on Civica Board of Directors.

LEHI, Utah–(BUSINESS WIRE)–Civica, Inc. (Civica, Civica Rx) today announced that Ned McCoy, currently Civica’s Chief Operating Officer, will succeed Martin VanTrieste as Civica’s President and Chief Executive Officer, effective June 1. VanTrieste will remain an advisor to the Company and continue serving on Civica’s Board of Directors. As part of this transition, McCoy will also join the Civica Board of Directors on June 1.

“Martin’s decision to come out of retirement four years ago to help us shape and launch Civica was critical to bringing together diverse stakeholders to create a more reliable and affordable approach to generic medicines,” said Dan Liljenquist, Chairman of the Board of Directors of Civica. “From leading the development of Civica’s future essential medicines manufacturing facility to executing numerous pivotal partnership agreements and, most recently, pioneering Civica’s initiative to manufacture and distribute affordable insulin, Martin’s impact will be felt for decades to come. We’re thrilled Martin will continue serving on our Board of Directors and will help guide the Civica team to build on the many successes during his tenure.”

VanTrieste commented, “It has been an honor to lead Civica and witness firsthand how our organization has improved so many lives – providing enough essential medicine to help treat over 30 million patients to date. Our team’s dedication and passion for building an innovative, transformative generic medication model constantly inspires me. I look forward to continuing to be a part of Civica as a member of the Board and supporting Ned as he takes on this exciting role.”

McCoy has provided day-to-day oversight for Civica’s growing manufacturing efforts, including the building of Civica’s state-of-the-art essential medicines manufacturing facility in Petersburg, VA, expected to be operational in early 2024. McCoy has led efforts to secure manufacturing partnerships for over 60 sterile injectable medications that hospitals use daily, helping Civica supply essential medicines and address chronic drug shortages, unpredictable price inflation, and predatory pricing. He has also been deeply involved with Civica’s commercial team and stakeholders, ensuring hospitals have the medicines they need when they need them. Most recently, McCoy orchestrated the partnership with Civica’s affordable insulin development partner, GeneSys Biologics, with the plan to bring Civica biosimilar insulins to market beginning in 2024.

Prior to Civica, McCoy served at Abbott for 32 years, where he led teams in Hospital Products, Pharmaceutical Products (now AbbVie), Nutrition and Corporate Mergers and Acquisitions. McCoy received his Bachelor and Master of Science degrees in Chemical Engineering from North Carolina State University.

Liljenquist continued, “On behalf of the Board, we’re thrilled that Ned will take on this new role, leveraging his strong track record of leading companies to significant growth and executing complementary partnerships. I, and the entire Board, have complete confidence that he will further build on Civica’s important work to serve even more patients and transform the medication landscape.”

McCoy commented, “I am honored to serve as the next CEO of Civica and continue our pivotal work of delivering quality generic medications that are available and affordable to everyone. Through much of my time at Civica, I have had the privilege of leading Civica’s operations, including helping to secure successful, long-term manufacturing partnerships and execute the building of our own manufacturing facility. I look forward continuing to work with our talented team and furthering our culture of innovation, excellence and dedication to improving patient lives with a new model for generic hospital and prescription medicines.”

Read more here.

Recent News

12/05/2022

Danville organization invests in Blacksburg’s CytoRecovery medical cell sorting company

Danville’s investment might mean a CytoRecovery presence in Danville, such as office operations or an internship at Danville Community College. CytoRecovery’s cell sorting could improve understanding of disease and development of drugs. CytoRecovery, an early-stage company that invented and patented less invasive cell sorting, will be able to bring its cell research platform to market

12/01/2022

Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

MANASSAS, Virginia – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4

11/16/2022

Alliance for Building Better Medicine Names Joy Polefrone as Executive Director

Joy Polefrone, Ph.D. will Lead the Organization in Its Mission to Create a Reliable Supply of Safe, High-Quality, and Affordable Medicines in the U.S. Richmond/Petersburg– Alliance for Building Better Medicine, a coalition of public and private sector stakeholders in the Richmond-Petersburg region, today announced that it has appointed Joy Marie Polefrone, Ph.D., as the organization’s executive director.